Current status of clinical outcome measures in inclusion body myositis: a systematised review

CONCLUSIONS: There are inconsistencies in using outcome measures in clinical studies in IBM. The core set measures developed by the IMACS group for other IIMs are not directly applicable to IBM. As a result, there is an unmet need for an IBM-specific core set of measures to facilitate the evaluation of new potential therapeutics for IBM.PMID:36762744 | DOI:10.55563/clinexprheumatol/ifacv3

Source: Clinical and Experimental Rheumatology - February 10, 2023 Category: Rheumatology Authors: Bhaskar Roy Matteo Lucchini James B Lilleker Namita A Goyal Elie Naddaf Brittany Adler Lindsay N Alfano Georgia A Malandraki Kendrea L Focht Garand David Mochel Umesh Badrising Pedro M Machado Ruben Pagkatipunan Leo Wang Melissa C Funaro Jens Schmidt Hani Source Type: research